Inside Out: Targeting Proteins on Cancer Cells

ADCs

How Lessons from Breast Cancer Are Shaping ADC Development Across Solid Tumors

David Alvaro, Ph.D.

Pharma's Almanac

Heme-Onc

Therapeutic and Diagnostic Advances Benefiting Patients with Hematologic Malignancies

Cynthia A. Challener, Ph.D.

Pharma's Almanac

Heme-Onc

The Next Generation of Targeted Therapies in Hematologic Malignancies

Oncolytic Viruses

Turning Oncolytic Viruses into Manufacturable Cancer Therapies

Luisa Amoedo Otero

Recipharm Advanced Bio

Oncolytic Viruses

Manufacturing Oncolytic Viruses: Where Complexity Demands Experience

Mathias Kahl

IDT Biologika

MRD

Measurable Residual Disease Moves Deeper Into Hematologic Cancer Development

Pharma's Almanac

BsAbs in Oncology

Bispecific Antibodies Move Into the Heme-Onc Mainstream

David Alvaro, Ph.D.

Pharma's Almanac

Pediatric Oncology

Why Pediatric Oncology Needs Its Own Drug Development Paradigm

David Alvaro, Ph.D.

Pharma's Almanac

Masked Antibody

Expanding the Oncology Therapeutic Window Through Masked Antibody Technology

Sean McCarthy, Ph.D; David Alvaro, Ph.D.

CytomX Therapeutics

Vaccine Development

New Vaccine Technologies Expand the Frontiers of Prevention and Treatment

Cynthia A. Challener, Ph.D.

Pharma's Almanac

Vaccines

Beyond Infectious Disease: Vaccines for Cancer and Chronic Conditions

Pharma's Almanac

LAIs

Seven Biotechs Developing Long-Acting Injectable Drugs

Vedangi Joshi

Nice Insight